中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2015年
8期
95-97
,共3页
罗格列酮%脓毒症%肺损伤%HMGB1%TNF-α%Th1%Th2
囉格列酮%膿毒癥%肺損傷%HMGB1%TNF-α%Th1%Th2
라격렬동%농독증%폐손상%HMGB1%TNF-α%Th1%Th2
rosiglitazone%sepsis%lung injury%HMGB1%TNF-α%Th1%Th2
目的：探讨罗格列酮辅助治疗对脓毒症肺损伤患者血清高迁移率族蛋白－1（high mobility group box1，HMGB1）、TNF－α及Th1／Th2影响研究。方法收集青海省中医院2013年8月～2014年8月收治的60例脓毒症肺损伤患者，按照用药方法随机分为实验组和对照组，各30例。对照组给予常规西医综合对症治疗，包括重症监护、胃肠减压、禁食水、补充血容量、抗炎、维持水和电解质平衡、改善微循环等。实验组在对照组治疗基础上给予患者罗格列酮，2次／天，2周为1个疗程，于1、3、7、14 d对所有患者的血清血清HMGB1、TNF－α及Th1／Th2进行检测。结果治疗后，与对照组相比，实验组患者各指标均显著改善，血清HMGB1水平降低显著（P＜0．05）；血清TNF－α水平降低较为显著（P＜0．05）；血清Th1／Th2比值降低显著（P＜0．05）。结论罗格列酮辅助治疗能够显著降低HMGB1、TNF－α水平及Th1／Th2比值。
目的：探討囉格列酮輔助治療對膿毒癥肺損傷患者血清高遷移率族蛋白－1（high mobility group box1，HMGB1）、TNF－α及Th1／Th2影響研究。方法收集青海省中醫院2013年8月～2014年8月收治的60例膿毒癥肺損傷患者，按照用藥方法隨機分為實驗組和對照組，各30例。對照組給予常規西醫綜閤對癥治療，包括重癥鑑護、胃腸減壓、禁食水、補充血容量、抗炎、維持水和電解質平衡、改善微循環等。實驗組在對照組治療基礎上給予患者囉格列酮，2次／天，2週為1箇療程，于1、3、7、14 d對所有患者的血清血清HMGB1、TNF－α及Th1／Th2進行檢測。結果治療後，與對照組相比，實驗組患者各指標均顯著改善，血清HMGB1水平降低顯著（P＜0．05）；血清TNF－α水平降低較為顯著（P＜0．05）；血清Th1／Th2比值降低顯著（P＜0．05）。結論囉格列酮輔助治療能夠顯著降低HMGB1、TNF－α水平及Th1／Th2比值。
목적：탐토라격렬동보조치료대농독증폐손상환자혈청고천이솔족단백－1（high mobility group box1，HMGB1）、TNF－α급Th1／Th2영향연구。방법수집청해성중의원2013년8월～2014년8월수치적60례농독증폐손상환자，안조용약방법수궤분위실험조화대조조，각30례。대조조급여상규서의종합대증치료，포괄중증감호、위장감압、금식수、보충혈용량、항염、유지수화전해질평형、개선미순배등。실험조재대조조치료기출상급여환자라격렬동，2차／천，2주위1개료정，우1、3、7、14 d대소유환자적혈청혈청HMGB1、TNF－α급Th1／Th2진행검측。결과치료후，여대조조상비，실험조환자각지표균현저개선，혈청HMGB1수평강저현저（P＜0．05）；혈청TNF－α수평강저교위현저（P＜0．05）；혈청Th1／Th2비치강저현저（P＜0．05）。결론라격렬동보조치료능구현저강저HMGB1、TNF－α수평급Th1／Th2비치。
Objective To investigate the effect of rosiglitazone on serum HMGB1,TNF-αand Th1/Th2 in patients with lung injury induced by sepsis.Methods 60 patients with sepsis lung injury in our hospital from August 2013 to August 2014, were randomly divided into experimental group and control group according to the medication methods, 30 cases in each group, control group was given conventional western medicine treatment, including intensive care, gastrointestinal decompression, fasting water, added blood volume, anti-inflammatory, maintenance of water and electrolyte balance, improve microcirculation, etc.On the basis of control group, experimental group was treated with rosiglitazone, two times per day, two weeks as a course of treatment.Serum HMGB1, TNF-α, Th1/Th2 were detected in 1, 3, 7, 14 days in all patients.ResuIts Compared with control group post-treatment,serum HMGB1,TNF-αand Th1/Th2 ratio were significantly decreased in the experimental group (P<0.05).ConcIusion Rosiglitazone can significantly reduce the levels of serum HMGB1,TNF-αand Th1/Th2.
